Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 2 institutions in 1 country.
Julie NiogretDepartment of Medical Oncology, Georges-François Leclerc Cancer Center, 21000 Dijon, France.ORCID 0000-0002-3563-4658
Valentin DerangèrePlatform of Transfer in Biological Oncology, Georges-François Leclerc Cancer Center, 21000 Dijon, France.
Corentin RichardUnit of Molecular Biology, Department of Biology and Pathology of Tumors, Georges-François Leclerc Cancer Center, 1 Rue du Professeur Marion, CEDEX, 21079 Dijon, France.ORCID 0000-0001-9732-0219
Lisa NuttinPlatform of Transfer in Biological Oncology, Georges-François Leclerc Cancer Center, 21000 Dijon, France.
François GhiringhelliDepartment of Medical Oncology, Georges-François Leclerc Cancer Center, 21000 Dijon, France.ORCID 0000-0002-5465-8305
Laure FavierDepartment of Medical Oncology, Georges-François Leclerc Cancer Center, 21000 Dijon, France.
Leila Bengrine LefevreDepartment of Medical Oncology, Georges-François Leclerc Cancer Center, 21000 Dijon, France.
Anthony BergeronUnit of Pathology, Department of Biology and Pathology of Tumors, Georges-François Leclerc Cancer Center, 21000 Dijon, France.
Laurent ArnouldUnit of Pathology, Department of Biology and Pathology of Tumors, Georges-François Leclerc Cancer Center, 21000 Dijon, France.
Romain BoidotUnit of Molecular Biology, Department of Biology and Pathology of Tumors, Georges-François Leclerc Cancer Center, 1 Rue du Professeur Marion, CEDEX, 21079 Dijon, France.ORCID 0000-0001-9956-1737
Centre Georges François Leclerc · FRCentre National de la Recherche Scientifique · FR
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Low-grade serous carcinoma represents a minority of serous carcinoma. Although they have better prognosis than high-grade serous carcinoma, they respond poorly to chemotherapy. Thus, it appears necessary to find other treatments such as targeted therapies. Since
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series. · full record | OpenQuestion